NASDAQ:ATXI Avenue Therapeutics 8/9/2024 Earnings Results & Report $0.40 -0.03 (-6.00%) As of 10/20/2026 02:05 PM Eastern Avenue Therapeutics missed analyst earnings expectations in results released August 9, 2024. The company reported EPS of -$6.43 versus the -$1.05 consensus estimate. Research:Profile Earnings Announcement Details Report DateAugust 9, 2024TimeAfter Market Closes Avenue Therapeutics EPS ResultsActual EPS-$6.43Consensus EPS -$1.05Beat/MissMissed by -$5.38One Year Ago EPSN/AAvenue Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAvenue Therapeutics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Avenue Therapeutics Earnings FAQ Did Avenue Therapeutics beat earnings estimates for the quarter? Avenue Therapeutics (NASDAQ:ATXI) reported earnings of -$6.43 per share for the quarter, missing the consensus estimate of -$1.05. The report was announced on Friday, August 9, 2024. When is Avenue Therapeutics' next earnings date? Avenue Therapeutics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Avenue Therapeutics on the company's earnings history page. Avenue Therapeutics Earnings HeadlinesAvenue Therapeutics Inc.February 10, 2026 | barrons.comAvenue Therapeutics announces Baergic Bio acquisition by AxsomeNovember 6, 2025 | msn.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 21 at 1:00 AM | Banyan Hill Publishing (Ad)Avenue Therapeutics Reports Positive Earnings Amid ChallengesAugust 22, 2025 | msn.comUniversity Avenue will be closed for repair due to a sinkhole in MorgantownJuly 20, 2025 | msn.com17-year-old dies from gunshot wound near Colley Avenue, police sayJuly 20, 2025 | msn.comSee More Avenue Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avenue Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avenue Therapeutics and other key companies, straight to your email. Email Address About Avenue TherapeuticsAvenue Therapeutics (NASDAQ:ATXI) is a specialty pharmaceutical company focused on developing and commercializing therapies for acute and other serious medical conditions. The company is headquartered in the United States and trades on the Nasdaq under the symbol ATXI. Avenue’s primary product candidate has been intravenous tramadol, an investigational formulation intended to provide short-term management of acute postoperative pain in adults who require an opioid analgesic in a medically supervised setting. The company has pursued regulatory approval in the United States and has conducted clinical and regulatory activities related to the product’s safety, efficacy and manufacturing. Avenue Therapeutics was established as a subsidiary of Fortress Biotech, a biopharmaceutical company that supports the development of medicines through a subsidiary-based model. Its activities have primarily centered on advancing its lead acute-pain program through the U.S. regulatory process rather than operating a broad commercial product portfolio.View Avenue Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Halliburton Gains Traction: Multiyear Upcycle AheadMeta Platforms' AI Comeback Faces an Earnings Test—And a $10 Billion ChargeCarMax's Double Upgrade Could Signal a Bigger TurnaroundD-Wave Stock Has 2 New Reasons for Investors to Pay AttentionTesla's Roadster Reveal Hints at 2 Much Bigger MovesThe AI Sell-Off Continues—These 3 Stocks Keep Raising Guidance AnywayRate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging Upcoming Earnings Comcast (10/22/2026)Spotify Technology (10/22/2026)Procter & Gamble (10/22/2026)Valero Energy (10/22/2026)Barclays (10/22/2026)Blackstone (10/22/2026)Nasdaq (10/22/2026)Bloom Energy (10/22/2026)Comfort Systems USA (10/22/2026)Honeywell International (10/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
